Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – ...

The identification of immune genes that distinguish patients with CRSwNP from healthy controls offers insight into disease ...

Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, ...

Dupilumab improved nasal polyp outcomes and asthma symptoms more than omalizumab in patients with CRSwNP and asthma, according to the head-to-head EVEREST phase 4 trial.

Most people with a condition known as chronic rhinosinusitis with nasal polyps (CRSwNP) are able to control their symptoms by using medicines that are sprayed into the nose or taken by mouth.

When looking specifically at the dominant cellular pattern, calprotectin levels were markedly higher in the non–EOS-CRSwNP and mixed CRSwNP groups vs the healthy control group: 324.5 (159.7) vs ...

The approval in adolescent patients was based on evidence from the phase 3 SINUS-24 and SINUS-52 trials (ClinicalTrials.gov Identifier: NCT02912468 and NCT02898454, respectively), which compared ...

UK-based pharmaceutical company GSK has reported positive outcomes from two Phase III trials of depemokimab for treating ...

Often associated with type 2 inflammation, CRSwNP is characterised by high levels of IL-5 in nasal polyp tissue and a tendency for nasal polyps to regrow post-surgery due to persistent inflammation.

As for the ability of tissue SERPINB10 to be a predictive indicator of postop CRSwNP recurrence, although a link was seen between CRSwNP recurrence and tissue eosinophil percentage (odds ratio [OR ...

CRSwNP is a chronic disease of the upper airway, driven in part by type 2 inflammation, that obstructs the sinuses and nasal passages. It can lead to breathing difficulties, ...

GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine headwinds.